New cocktail therapy hopes to tackle tough lung cancer

NCT ID NCT03381274

Ongoing Disease control Sponsor: MedImmune LLC Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jul 14, 2026 · Updated 2 times

Summary

This early-stage trial tests two new drug combinations in people with advanced EGFR-mutated non-small cell lung cancer whose previous treatments have stopped working. The study combines a biologic (oleclumab) with either the targeted drug osimertinib or another experimental drug (AZD4635). The main goals are to check safety and see if the tumors shrink. About 43 adults are taking part.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: Oleclumab (a biologic) combined with either osimertinib (Tagrisso) or AZD4635 (a drug)
What this could lead to: If successful, this could point toward new combination treatments that help control advanced EGFR-mutated lung cancer after other therapies stop working.
What could go wrong: This is an early-phase trial with only 43 participants, so results may not apply to all patients. The combinations may cause serious side effects or fail to improve outcomes.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CARCINOMA, NON-SMALL-CELL LUNG are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

non-small cell lung carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CARCINOMA, NON-SMALL-CELL LUNG

Contacts and locations

Locations

Research Site

La Jolla, California, 92093, United States
Research Site

San Francisco, California, 94143, United States
Research Site

Aurora, Colorado, 80045, United States
Research Site

New Haven, Connecticut, 06510, United States
Research Site

Atlanta, Georgia, 30322, United States
Research Site

Chicago, Illinois, 60611, United States
Research Site

Baltimore, Maryland, 21224, United States
Research Site

New York, New York, 10032, United States
Research Site

Houston, Texas, 77030, United States
Research Site

Seoul, 03080, South Korea
Research Site

Seoul, 05505, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Taichung, 40705, Taiwan

More trials for these conditions

Other studies related to the condition(s) this trial covers.